Evidence map›Paper›PMID 41742883›Full record

SynthesisHaematologica2026

Prognostic implications of myelodysplasia-related gene mutations in

Yu-Sung Chang, Yi-Wei Lee, Chieh-Yu Liu, Jad Othman, Jan-Niklas Eckardt, Qianghua Zhou, Feng-Ming Tien, Ting-Wei Lyu, Xavier Cheng-Hong Tsai, Chien-Chin Lin and 7 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. AML, Myelodysplasia-Related: Beyond Classification-Toward Precision Decision-Making.Mediterranean journal of hematology and infectious diseases · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yu-Sung ChangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei.
Yi-Wei LeeDepartment of Internal Medicine, Taipei Medical University Hospital, Taipei.
Chieh-Yu LiuInstitute of Community Health Care, College of Nursing, National Yang Ming Chiao Tung University, Taipei.
Jad OthmanDepartment of Medical and Molecular Genetics, King's College London, London, United Kingdom; Department of Haematology, Royal North Shore Hospital, Sydney, Australia; Faculty of Medicine and Health, University of Sydney, Sydney.
Jan-Niklas EckardtDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden.
Qianghua ZhouDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto.
Feng-Ming TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei.
Ting-Wei LyuDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu.
Xavier Cheng-Hong TsaiDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei.
Chien-Chin LinDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei.
Hong ChangDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Department of Laboratory Hematology, University Health Network, Toronto.
Bor-Sheng KoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei.
Wen-Chien ChouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei.
Christoph RölligDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden.
Nigel RussellDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, London.
Richard DillonDepartment of Medical and Molecular Genetics, King's College London, London, United Kingdom; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London.
Hsin-An HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Division of General Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei. hsinanhou@ntu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NPM1-mutated (NPM1mut) acute myeloid leukemia (AML) is generally classified as favorable-risk under the 2022 European LeukemiaNet (ELN-2022) guidelines, except in the presence of FLT3-internal tandem duplication or adverse-risk cytogenetics. However, the prognostic significance of co-occurring myelodysplasia-related gene (MRG) mutations remains unclear, with prior studies yielding inconsistent results. To clarify this issue, we conducted a systematic review and meta-analysis in accordance with PRISMA guidelines, searching PubMed, Embase, and MEDLINE through March 2025. MRG mutations were defined as pathogenic variants in ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 and RUNX1, and the primary analysis incorporated studies regardless of RUNX1 inclusion. Data from ten cohorts across nine studies (1 of which included an independent validation cohort), encompassing a total of 4,363 patients, were analyzed. Of these, 655 patients (15.0%) harbored co-occurring MRG mutations. Among the patients with ELN-2022 intermediate risk (N=1,294), 108 (8.3%) had MRG mutations. The presence of MRG mutations was significantly associated with inferior overall survival (pooled hazard ratio [HR]=1.30; 95% confidence interval [CI]: 1.11-1.51; P<0.001; I²=39.2%), shorter event-free survival (HR=1.43; 95% CI: 1.11-1.85; P=0.006; I²=18.2%), and lower complete remission rates (risk ratio=0.94; 95% CI: 0.90-0.99; P=0.01; I²=0.0%). Subgroup analyses confirmed the adverse prognostic impact in patients receiving intensive therapy and those classified as ELN-2022 favorable risk. These findings suggest that MRG mutations confer an adverse prognostic effect in NPM1mut AML and support the integration of MRG status into future risk stratification frameworks for NPM1mut AML.

Indexed as

Leukemia, Myeloid, AcuteMutationMyelodysplastic SyndromesNuclear ProteinsHumansNucleophosminPrognosisNPM1 protein, humanNuclear ProteinsNucleophosmin

Identifiers

PMID41742883
PMCPMC13530955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.